Weimin Tang, PhD

The Global Business Development team and the Corporate Development team work closely to support I-Mab’s vision of becoming a fully integrated innovative biopharmaceutical company.

The Global Business Development team is led by Weimin Tang, PhD, who is responsible for the company’s overall business development strategy. Dr. Tang has a strong track record of successful global pharmaceutical business development. During his 15-year tenure in pharma business development, he worked at Pfizer, Bristol-Myers Squibb, Sanofi, and Johnson & Johnson. He also was Acting CEO of Hengrui Therapeutics, a US branch of Hengrui Pharmaceuticals. With broad experience in global and China marketplaces, the Business Development team works closely with other units within I-Mab to identify external partnering opportunities and a competitive pipeline. I-Mab remains actively engaged in in-licensing and out-licensing activities.